1. Antibody

    Comments Leave a Comment

    1-15 of 145 1 2 3 4 5 6 7 8 9 10 »
    1. Mentioned In 145 Articles

    2. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      ...domized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931,...
      Read Full Article
      Mentions: Antibody COG
    3. APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual ...

      ...“Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients ... Sorry, an error occurred while processing your request....
      Read Full Article
    4. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      ...eylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients...
      Read Full Article
      Mentions: Antibody Treatment
    5. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      ...m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program. The monoclonal anti-GD antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients...
      Read Full Article
      Mentions: Antibody Treatment
    6. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      ...apy because it can improve the cytolytic function of NK cells against neuroblastoma cells and could lower the antibody dose required for efficacy, thereby reducing toxicity. The effect of IL-2 may vary among individuals ...
      Read Full Article
      Mentions: Antibody
    7. High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

      High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
      ...hich is abundant on the surface of neuroblastoma cells, is targeted by an FDA-approved therapeutic monoclonal antibody and is an attractive tumor-associated antigen for cellular immunotherapy. Chimeric antigen receptor (...
      Read Full Article
    8. Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in ...

      VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal ...
      Read Full Article
    9. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      ...with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy. Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblast...
      Read Full Article
      Mentions: Antibody Treatment
    10. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      ...tion with granulocyte-macrophage colony-stimulating factor. The influence of body weight and human anti-human antibody (HAHA) on the pharmacokinetics (PK) of hu3F8, and the effect of de novo anti-GD2 response on patient ...
      Read Full Article
      Mentions: Antibody
    11. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      ...arol E, Loibner H, Ladenstein R, Lode HN Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25mg/m2/d; 8-20h) in combination with cytokines and 13-cis retinoic acid (RA) prol...
      Read Full Article
    12. 1-15 of 145 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Antibody

    1. An anti-tumor antibody can improve adoptive T-cell therapy to a surprising extent.
      In Recruiting the Entire Immune System to Attack Cancer
    2. The antibody-driven innate response creates an environment such that when the T cells come in, they can kill the tumor. In its absence, the tumor cells establish an environment where the T cells don't work very well.
      In Recruiting the Entire Immune System to Attack Cancer
    3. One of the regulators we uncovered normally enhances effector T cell differentiation at the expense of generating memory T cells and T cells that orchestrate antibody production.
      In Important regulators of immune cell response identified